Duloxetin - a new tool in pharmacotherapy of urinary incontinence in women
- Authors: Mazo EВ1, Iremashvili VV1
-
Affiliations:
- Issue: No 6 (2004)
- Pages: 57-60
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/276339
- ID: 276339
Cite item
Full Text
Abstract
Urinary incontinence (UI) is represented clinically by stress, urgent,
mixed forms. Until recently, effective pharmacological treatment
of stress UI was absent. Now, attempts are made to try duloxetin
to raise efficacy of conservative treatment and quality of life in patients
with stress and mixed UI. A large, double blind, placebo-controlled,
randomized phase II trial provided data on efficacy of duloxetin
in the treatment of stress and mixed UI in women. Duloxetin
led to a decrease in the number of incontinence episodes, a rise in
quality of life. It was rather effective in severe UI. Phase III trial of
duloxetin in a dose 80 mg/day reduced the number of incontinence
episodes by 50% in most of the patients and in some of them cured
the patients.
mixed forms. Until recently, effective pharmacological treatment
of stress UI was absent. Now, attempts are made to try duloxetin
to raise efficacy of conservative treatment and quality of life in patients
with stress and mixed UI. A large, double blind, placebo-controlled,
randomized phase II trial provided data on efficacy of duloxetin
in the treatment of stress and mixed UI in women. Duloxetin
led to a decrease in the number of incontinence episodes, a rise in
quality of life. It was rather effective in severe UI. Phase III trial of
duloxetin in a dose 80 mg/day reduced the number of incontinence
episodes by 50% in most of the patients and in some of them cured
the patients.
References
- Abrams P., Cardozo L., Fall M. et al. The standardization of terminology of lower urinary tract function: report from the Standardization Subcommittee of the International Continence Society. Neurourol. Urodyn. 2002; 21:167.
- Thorn D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J. Am.Geriatr. Soc. 1998; 46: 473-480.
- Wilson I., Brown J. S., Shin G. P. et al. Annual direct cost of urinary incontinence. Obstetr. and Gynecol. 2001; 98:398-406.
- Hampel C., Wienhold D., Benken N. et al. Definition of overactive bladder and epidemiology of urinary incontinence. Urology 1997; 50:4.
- Dmochowski R. R., Miklos J. R., Norton P. A. et al. Duloxetine versus placebo for the treatment of North American woman with stress urinary incontinence. J. Urol. (Baltimore) 2003; 170:1259-1263.
- Elia. G., Bergman A. Pelvic muscle exercises: when do they work? Obstetr. and Gynecol. 1993; 81:283-286.
- Lagro-Janssen Т., Van Weel С. Long-term effect of treatment of female incontinence in general practice. Br. J. Gen. Pract. 1998; 48:1735.
- Brown J. S., Waetjen L. E., Subak L. L. et al. Pelvic organ prlapse surgery in the United States. Am. J. Obstetr. Gynecol. 2002; 186:712.
- Espey M. J., Du H. J., Downie J. W. Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation in cats. Brain Res. 1998; 798:101.
- Danuser H., Thor К. В. Spinal 5-HT2 receptor-mediated facilitation of pudendal nerve reflexes in the anaesthetized cat. Br.J. Pharmacol. 1996; 118:150.
- Gajewski J., Downie J. W., Awad S. A. Experimental evidence for a central nervous system site of action in the effect of the alpha-adrenergic blockers on the external urinary sphincter. J. Urol. (Baltimore) 1984; 132:403.
- Downie J. W., Bialik G. J. Evidence for a spinal site of action of clonidine on somatic and viscerosomatic reflex activity evoked on the pudendal nerve in cats. J. Pharmacol. Exp.Ther. 1988; 246:352.
- Espey M. J., Downie J. W., Fine A. Effect of 5-HT receptor and adrenoceptor antagonists on micturition in conscious cats. Eur.J. Pharmacol. 1992; 221:167.
- Thor К. В., Katofiasc M. A. Effects of duloxetine, a combined serotonin and norepinephrin reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J. Pharmacol. Exp. Ther. 1995; 274:1014.
- Katofiasc M. A., Nissen J., Audia J. E., Thor К. В. Comparison of the effects of serotonin selective, norepinephrine selective and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. Life Sci. 2002; 71:1227.
- Zinner N., Thor К. В., Yalcin I. et al. Efficacy and safety of duloxetine in stress urinary incontinence patients. In: Proceedings of the 19th Annual meeting of Urodynamics society. San Diego: The Society; 1998.
- Norton P. A., Zinner N. R., Yalcin I. et al. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am. J. Obstetr. Gynecol. 2002; 187:40-48.
- Bump R. C., Norton P. A., Zinner N. R. et al. Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response. Obstetr. and Gynecol. 2003; 102:76-83.
Supplementary files
